Beyond Suppression: Rethinking Rosacea Through Inflammation

Most rosacea treatment protocols are built around a category error.

They treat what the skin shows, redness, flushing, papules, rather than what's driving it: a sustained cycle of vascular hyperreactivity and barrier breakdown. Topical suppression interrupts the visibility. It doesn't interrupt the cascade. And so the skin quiets temporarily, then responds again because the underlying biology hasn't changed.

For the estimated 16 million Americans living with rosacea, that cycle is the treatment. For patients with skin of color, the problem is compounded: a diagnostic model built around visible erythema in lighter skin types routinely misses the disease entirely in Fitzpatrick IV–VI, delaying treatment until the inflammatory burden is significantly higher.

The inflammation-first model starts from a different premise: that the goal isn't suppression it's resetting how the skin responds.

Join Valerie Callender, MD, President of the American Acne & Rosacea Society and founder of Callender Dermatology & Cosmetic Center, for a mechanism-driven, protocol-grounded discussion on what changes clinically when you lead with inflammation.

Drawing on her extensive research across diverse patient populations and decades of clinical experience treating Fitzpatrick types I through VI, Dr. Callender presents the inflammation-first framework — and shows how the Aerolase Neo Elite, with its 650-microsecond 1064nm pulse, becomes the first laser platform that can execute this approach safely and effectively across all skin types. Deep dermal targeting of vascular and inflammatory structures. No epidermal thermal burden. No ceiling on who qualifies for treatment.

Key Takeaways:

• The inflammatory cascade in detail — vascular hyperreactivity, innate immune activation, barrier dysfunction, and why addressing all three matters for lasting outcomes.
• Where conventional therapies structurally fail — the recurrence problem with antibiotics, the limits of topical rotation, and why standard laser and IPL platforms create an epidermal thermal load that makes them unreliable in sensitive and darker skin.
• How the Neo Elite's 650-microsecond pulse changes the equation — selective targeting of hemoglobin and inflammatory mediators at depth, without the surface barrier disruption that limits other platforms.
• Rosacea in skin of color: a misdiagnosis problem, not just a treatment problem — how an inflammation-first protocol built on 1064nm opens access for Fitzpatrick IV–VI patients who have been systematically excluded from laser-based rosacea care.
• A structured treatment protocol you can implement Monday — initial series parameters, maintenance scheduling, and combination sequencing with topicals and barrier-supportive skincare.
• Real patient outcomes across skin types — case-based review organized by mechanism, safety profile, and long-term inflammatory trajectory.

‍

Register to watch this webinar live on April 15, 2026 at 8:00pm EST!

‍

Presented by Valerie D. Callender, MD, FAAD

President, American Acne & Rosacea Society | Founder & Medical Director, Callender Dermatology & Cosmetic Center

Board-certified dermatologist who is known for her sensitive and cutting-edge approach to the management of hair loss in women and the treatment of pigmentation disorders. Dr. Callender has performed leadership roles in many dermatological organizations, including the Women’s Dermatologic Society and the Skin of Color Society.